Kepler Capital Reaffirms Their Buy Rating on Valneva (0OB3)
TipRanks (Thu, 22-Jan 4:24 AM ET)
Valneva Provides Update on Chikungunya Vaccine IXCHIQ
Globe Newswire (Mon, 19-Jan 12:00 PM ET)
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Globe Newswire (Fri, 9-Jan 1:00 AM ET)
Globe Newswire (Wed, 10-Dec 11:45 AM ET)
Valneva to Further Consolidate its Operations in France
Globe Newswire (Wed, 26-Nov 11:30 AM ET)
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
Globe Newswire (Wed, 26-Nov 1:00 AM ET)
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
Globe Newswire (Thu, 20-Nov 1:00 AM ET)
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Globe Newswire (Tue, 4-Nov 1:00 AM ET)
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Globe Newswire (Mon, 27-Oct 12:45 PM ET)
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Valneva Se - American Depositary Shares trades on the NASDAQ stock market under the symbol VALN.
As of January 26, 2026, VALN stock price declined to $9.24 with 7,807 million shares trading.
VALN has a beta of 1.42, meaning it tends to be more sensitive to market movements. VALN has a correlation of 0.13 to the broad based SPY ETF.
VALN has a market cap of $801.18 million. This is considered a Small Cap stock.
Last quarter Valneva Se - American Depositary Shares reported $34 million in Revenue and -$.61 earnings per share. This fell short of revenue expectation by $-16 million and missed earnings estimates by -$.31.
In the last 3 years, VALN traded as high as $17.05 and as low as $3.62.
VALN has outperformed the market in the last year with a return of +94.9%, while the SPY ETF gained +14.8%. However, in the most recent history, VALN shares have underperformed the stock market with its stock returning -4.5% in the last 3 month period and -6.4% for the last 2 week period, while SPY has returned +3.4% and -0.2%, respectively.
VALN support price is $9.38 and resistance is $10.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VALN shares will trade within this expected range on the day.